Cargando…
Functional Nanomedicines for Targeted Therapy of Bladder Cancer
Bladder cancer is one of most common malignant urinary tract tumor types with high incidence worldwide. In general, transurethral resection of non-muscle-invasive bladder cancer followed by intravesical instillation of chemotherapy is the standard treatment approach to minimize recurrence and delay...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635105/ https://www.ncbi.nlm.nih.gov/pubmed/34867408 http://dx.doi.org/10.3389/fphar.2021.778973 |
_version_ | 1784608236294373376 |
---|---|
author | Tang, Chao Liu, Heng Fan, Yanpeng He, Jiahao Li, Fuqiu Wang, Jin Hou, Yuchuan |
author_facet | Tang, Chao Liu, Heng Fan, Yanpeng He, Jiahao Li, Fuqiu Wang, Jin Hou, Yuchuan |
author_sort | Tang, Chao |
collection | PubMed |
description | Bladder cancer is one of most common malignant urinary tract tumor types with high incidence worldwide. In general, transurethral resection of non-muscle-invasive bladder cancer followed by intravesical instillation of chemotherapy is the standard treatment approach to minimize recurrence and delay progression of bladder cancer. However, conventional intravesical chemotherapy lacks selectivity for tumor tissues and the concentration of drug is reduced with the excretion of urine, leading to frequent administration and heavy local irritation symptoms. While nanomedicines can overcome all the above shortcomings and adhere to the surface of bladder tumors for a long time, and continuously and efficiently release drugs to bladder cancers. The rapid advances in targeted therapy have led to significant improvements in drug efficacy and precision of targeted drug delivery to eradicate tumor cells, with reduced side-effects. This review summarizes the different available nano-systems of targeted drug delivery to bladder cancer tissues. The challenges and prospects of targeted therapy for bladder cancer are additionally discussed. |
format | Online Article Text |
id | pubmed-8635105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86351052021-12-02 Functional Nanomedicines for Targeted Therapy of Bladder Cancer Tang, Chao Liu, Heng Fan, Yanpeng He, Jiahao Li, Fuqiu Wang, Jin Hou, Yuchuan Front Pharmacol Pharmacology Bladder cancer is one of most common malignant urinary tract tumor types with high incidence worldwide. In general, transurethral resection of non-muscle-invasive bladder cancer followed by intravesical instillation of chemotherapy is the standard treatment approach to minimize recurrence and delay progression of bladder cancer. However, conventional intravesical chemotherapy lacks selectivity for tumor tissues and the concentration of drug is reduced with the excretion of urine, leading to frequent administration and heavy local irritation symptoms. While nanomedicines can overcome all the above shortcomings and adhere to the surface of bladder tumors for a long time, and continuously and efficiently release drugs to bladder cancers. The rapid advances in targeted therapy have led to significant improvements in drug efficacy and precision of targeted drug delivery to eradicate tumor cells, with reduced side-effects. This review summarizes the different available nano-systems of targeted drug delivery to bladder cancer tissues. The challenges and prospects of targeted therapy for bladder cancer are additionally discussed. Frontiers Media S.A. 2021-11-16 /pmc/articles/PMC8635105/ /pubmed/34867408 http://dx.doi.org/10.3389/fphar.2021.778973 Text en Copyright © 2021 Tang, Liu, Fan, He, Li, Wang and Hou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Tang, Chao Liu, Heng Fan, Yanpeng He, Jiahao Li, Fuqiu Wang, Jin Hou, Yuchuan Functional Nanomedicines for Targeted Therapy of Bladder Cancer |
title | Functional Nanomedicines for Targeted Therapy of Bladder Cancer |
title_full | Functional Nanomedicines for Targeted Therapy of Bladder Cancer |
title_fullStr | Functional Nanomedicines for Targeted Therapy of Bladder Cancer |
title_full_unstemmed | Functional Nanomedicines for Targeted Therapy of Bladder Cancer |
title_short | Functional Nanomedicines for Targeted Therapy of Bladder Cancer |
title_sort | functional nanomedicines for targeted therapy of bladder cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635105/ https://www.ncbi.nlm.nih.gov/pubmed/34867408 http://dx.doi.org/10.3389/fphar.2021.778973 |
work_keys_str_mv | AT tangchao functionalnanomedicinesfortargetedtherapyofbladdercancer AT liuheng functionalnanomedicinesfortargetedtherapyofbladdercancer AT fanyanpeng functionalnanomedicinesfortargetedtherapyofbladdercancer AT hejiahao functionalnanomedicinesfortargetedtherapyofbladdercancer AT lifuqiu functionalnanomedicinesfortargetedtherapyofbladdercancer AT wangjin functionalnanomedicinesfortargetedtherapyofbladdercancer AT houyuchuan functionalnanomedicinesfortargetedtherapyofbladdercancer |